News By Tag
* Market Research
* More Tags...
News By Place
World Sleep Disorders Market, 2005-2010: A Market With High Growth Potential
Bharatbook.com is proud to announce the addition of report "World Sleep Disorders Market, 2005-2010: A Market With High Growth Potential" to their offering.
The purpose of this market report is to examine the factors that will influence the market and examine why It has a forecast for the market to grow to over $4.4 billion by 2010. The imminent pipeline products are examined in detail and their potential strengths and weaknesses compared. The futures of the older products are assessed. Non-product related factors are considered as the insomnia treatment market has attracted considerable negativity associated with poor side effects and in particular dependency.
The potential for market growth is enormous with only 10% of the estimated potential patient population of 150 million using prescribed pharmaceutical products for insomnia. Although insomnia is by far the most common sleep disorder, this report also considers the markets for:
Restless Leg Syndrome (RLS)
Obstructive Sleep Apnea (OSA).
Sanofi-Aventis is the leading company in the sleep disorder market, but over 25 companies are mentioned in this report. The report assesses which companies and products will be key companies by 2010.
Why you should buy this report :
It is a market that will more than double in size by 2010.
It is a market that will change from one dominant product to one with at least 5 key products.
Characteristics of an ideal sleep disorder treatment are compared with the current and pipeline products.
Ambien is key product for Sanofi-Aventis and is at a pivotal point in its life cycle. How this will affect the future sales levels for Sanofi-Aventis is assessed.
Sanofi-Aventis and Sepracor have significantly increased their level of DTC advertising. The importance of this and other non-product related factors are considered.
For anyone with or considering involvement with the sleep disorder market this report is the most recently published report to examine and consider all of the salient factors.
Companies Mentioned in This Report :
Alliance Pharma, Arena Pharmaceutical, Astellas, Celgene, Cephalon, Eli Lilly, Fujisawa Pharmaceutical
GSK, King Pharmaceuticals, Lundbeck, Merck, Merck KgaA, Neurocrine Bioscience, Neurogen, Novartis
Organon, Orphan, Pfizer, Sanofi-Aventis, Sepracor, Shering AG, Shire, Somaxon, Takeda, Pharmaceutical, Teva, Wyeth/Elan, Yamanouchi
For more information, kindly visit :